.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,309,671

« Back to Dashboard

Details for Patent: 6,309,671

Title: Stable glassy state powder formulations
Abstract:A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (T.sub.g) and a recommended storage temperature (T.sub.s), wherein the difference between T.sub.g and T.sub.s is at least about 10.degree. C. (i.e. T.sub.g -T.sub.s is greater than 10.degree. C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.
Inventor(s): Foster; Linda C. (Mountain View, CA), Kuo; Mei-chang (Palo Alto, CA), Billingsley; Shelia R. (Sunnyvale, CA)
Assignee: Inhale Therapeutic Systems (San Carlos, CA)
Filing Date:Oct 14, 1997
Application Number:08/950,385
Claims:1. A powdered, dispersible composition suitable for inhalation and which maintains a stable dispersibility over time, comprising:

a pharmaceutically-acceptable glassy matrix, and

a pharmacologically active material within the glassy matrix, wherein said composition possesses a glass transition temperature, Tg, between 35.degree. C. and 200.degree. C. and wherein sad stable dispersibility over time is characterized by a delivered dose efficiency of at least 30 percent, when said composition is stored at a storage temperature, Ts, that is at least 10.degree. C. lower than Tg, over a time course of one month.

2. The composition of claim 1, characterized by a delivered dose efficiency of at least 40 percent when stored at said Ts over a time course of one month.

3. The composition of claim 1, characterized by a delivered dose efficiency of at least 50 percent when stored at said Ts over a time course of one month.

4. The composition of claim 1 comprising powder particles having an outer surface, wherein the outer surface of said particles is in a glassy state.

5. The composition of claim 1, for pulmonary administration.

6. The composition of claim 1, characterized by a delivered dose efficiency of at least 30 percent when stored at a storage temperature, Ts, that is at least 10.degree. C. lower than Tg, over a time course of 3 months.

7. The composition of claim 1, further characterized by an initial delivered dose efficiency which remains substantially unchanged over said time course.

8. The composition of claim 1, further characterized by a moisture uptake profile which allows absorption of up to about 5 percent moisture while maintaining a difference between Tg and Ts (Tg-Ts) of at least 10.degree. C.

9. The composition of claim 1, wherein the difference between Tg and Ts (Tg-Ts) is at least 20.degree. C.

10. The composition of claim 1, wherein the difference between Tg and Ts (Tg-Ts) is at least 30.degree. C.

11. A powdered composition having a stable dispersibility over time, comprising:

(i) a first respirable powdered component comprising the composition of claim 5, and

(ii) a second, nonrespirable powdered component comprising a powdered, pharmaceutically-acceptable carrier.

12. The composition of claim 1, having a Tg value greater than 45.degree. C.

13. The composition of claim 1, having a Tg value greater than 55.degree. C.

14. The composition of claim 1, wherein the glassy matrix comprises a glass former selected from the group consisting of carbohydrates, carbohydrate derivatives, carbohydrate polymers, organic carboxylic acid salts, synthetic organic polymers, proteins, peptides, amino acids, and mixtures thereof.

15. The composition of claim 14, wherein the glassy matrix comprises a glass former selected from the group consisting of sodium citrate, raffinose, lactose, trehalose, maltotriose, maltodextrin, maltose, glucopyranosyl-sorbitol, glucopyranosyl-mannitol, polydextrose, sucrose, cyclodextrin, casein, human serum albumin, hydroxyethyl starch, stachyose, magnesium gluconate, cellobiose, and mixtures thereof.

16. The composition of claim 1 in a container, in combination with labeling instructions for storing the composition at said storage temperature, Ts.

17. The composition of claim 16, wherein said container includes a moisture barrier.

18. The composition of claim 16 in unit dosage form, wherein said labeling instructions further include instructions for treating pulmonary or systemic disease in a mammalian subject.

19. A process for maintaining the dispersibility of a powdered composition over time, comprising:

(i) forming a solution comprising a solvent, a glass former capable of forming a glassy matrix, and a pharmacologically active material,

(ii) removing the solvent from said solution under conditions effective to form a powdered composition suitable for inhalation, said composition comprising a glassy matrix containing the pharmacologically active material and having a glass transition temperature, Tg, between 22.degree. C. and 200.degree. C., and

(iii) storing the composition over a time course of at least one month at a storage temperature, Ts, that is at least 10.degree. C. lower than the Tg value of said composition.

20. The process of claim 19, effective to form a powdered composition, which, after said storing, is characterized by a delivered dose efficiency of at least 30 percent.

21. The process of claim 19, wherein the solvent is removed by spray drying.

22. The process of claim 19, wherein the solvent is removed by evaporative drying.

23. The process of claim 19, wherein the solvent is removed by chemical precipitation.

24. The process of claim 19, wherein the solvent is water or ethanol.

25. The process of claim 19, wherein the difference between Tg and Ts (Tg-Ts) is at least 20.degree. C.

26. The process of claim 25, wherein the difference between Tg and Ts (Tg-Ts) is at least 30.degree. C.

27. The process of claim 19, wherein the Tg value of said composition is greater than 45.degree. C.

28. The process of claim 27, wherein the Tg value of said composition is greater than 55.degree. C.

29. The process of claim 19, wherein said storing step comprises storing the composition at a storage temperature, Ts, ranging from 2.degree. C. to 30.degree. C.

30. The process of claim 19, wherein the glassy matrix comprises a glass former selected from the group consisting of carbohydrates, carbohydrate derivatives, carbohydrate polymers, organic carboxylic acid salts, synthetic organic polymers, proteins, peptides, amino acids, and mixtures thereof.

31. The process of claim 30, wherein the glass former is selected from the group consisting of sodium citrate, raffinose, lactose, trehalose, maltotriose, maltodextrin, maltose, glucopyranosyl-sorbitol, glucopyranosyl-mannitol, polydextrose, sucrose, cyclodextrin, casein, human serum albumin, hydroxyethyl starch, stachyose, magnesium gluconate, cellobiose, and mixtures thereof.

32. The composition of claim 11, wherein said first respirable component comprises particles having a maximum particle size of about 10 microns, with the majority of particles in a size range from about 1 to 5 microns, and wherein said second, nonrespirable component comprises particles in a size range from about 15 to 100 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc